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In the treatment of cancer or of any other disease, the
physician or surgeon wishes to give the patient the most
effective treatment. On some occasions cure is almost certain,
e.g. following excision of a small rodent ulcer; on others
treatment will be based upon a judgement designed to offer
the greatest possibility of symptomatic relief and long term
survival with minimal immediate and delayed toxicity. The
mixture of perceived wisdom, medical prejudice and patient
preference which forms the advice given and which leads to
an agreed form of therapy arises in part from analysis of the
medical literature, recognising that many questions remain
unanswered.
For the last 20 to 30 years, the profession has increasingly
turned to the cooperative clinical study or randomised
clinical trial in order to offer more effective treatment with
the minimum of wasted time. After Phase I and Phase II
studies clinical trials are considered for those compounds or
approaches which seem most promising, the comparison
being between the new approach and that which is standard.
Where the currently accepted treatment is of a similar
nature to that proposed there is little ethical or practical
difficulty in conducting a trial since the situation is under-
stood by doctors, by patients and by ethical committees.
Where the choice lies between an established and a new
operation it may be more difficult to recruit patients because
of surgical prejudice, but there are no conflicts of interest for
the patient or for the ethical committee since the approach to
therapy is uniform.
The real problem arises when an attempt is made to com-
pare different forms of therapy, e.g. surgery versus
radiotherapy. Here the implications of a randomised clinical
trial come into very sharp focus. The established prejudices
of surgeons, medical oncologists and radiotherapists may
cause them to doubt the validity of the question being asked
and the proposal may cause unease in ethical committees.
The most important recent example of this in the United
Kingdom concerned the Medical Research Council's study of
immediate versus deferred orchidectomy in patients with pro-
static cancer. The concept that the medical profession did not
know whether immediate or deferred therapy was correct was
unsettling enough. The idea that they should test the
hypothesis by randomising patients to orchidectomy at diag-
nosis or only upon progression was seen by many as
intolerable.
The correspondence at that time from those opposed to
the trail was angled towards the concept that patients might
be receiving orchidectomy unnecessarily and without their
informed consent. The opposite view, that it was possible
that half the patients would be spared orchidectomy or at
feast would have the operation deferred until it was clinically
necessary was ignored. Certain ethical committees found the
study too difficult; others found it easy to accept the need for
orchidectomy, but more difficult to consider the possibility of
deferred treatment. Despite these challenges and the sincerely
held convictions of many surgeons, radiotherapists and
others, urologists were agreed that an answer to this question
was most desirable (Stamey, 1985). Fortunately this study
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continues and it seems that the MRC will be able to answer
this basic and important question before the end of this
decade.
In this issue, Drs Moore, O'Sullivan and Tannock question
the treatment strategies of urologic oncologists as they app-
roach patients affected by localised prostatic cancer, locally
advanced bladder cancer and metastatic renal cell carcinoma.
Controversies exist in all these areas and a group of 227
urologists, radiation oncologists and medical oncologists
have now been surveyed on two occasions. Initially the doc-
tor was asked which treatment he would select if he was a
patient, was advised of the existence of certain clinical trials
and was asked whether he would agree to be randomised in
such a trial; if not he was requested to give his reasons. This
survey showed substantial disagreement amongst the experts.
The present contribution attempts to determine the impact
of the results of the previous questionnaire upon this same
group of people. A few modified their view, but only 29%
would allow themselves, if patients, to be entered into one of
the relevant clinical trials despite the fact that 58% felt it
reasonable to offer their patients entry to such studies. This
questionnaire forced the physician and surgeon to consider
options in therapy and to conclude from a patient's view-
point whether it was sensible and reasonable to attempt to
obtain further information by means of a randomised clinical
trial. If the forms of therapy being tested were similar more
physicians were willing to be randomised. Where there was a
major difference, e.g. between radiotherapy and radical oper-
ation or between operation and no operation the decision
was more difficult to make and the potential entry rate much
lower.
Very few patients are entered into clinical trials, probably
no more than 3% (Crawford, 1990). There is no doubt that
these are inconvenient to the doctor who must spend more
time explaining the situation to the patient, must be confident
that randomisation is ethically correct and must monitor the
outcome closely. They are inconvenient to the hospital since
clinical trials often result in extra investigations and an in-
creased number of hospital visits, an issue now being
critically considered in the United States because of rising
costs (McKenna, 1990; McKenna et al., 1990; Henney et al.,
1990). They are also unsettling for the patient who is made
chillingly aware of the lack of certainty of his medical
advisor. In addition there is always the question of informed
consent, a concept which in my view protects the doctor
rather than the patient in the majority of instances.
One of the problems faced by those interested in clinical
trials has been whether it is possible to increase the percen-
tage of patients with a given condition entered into the trials
in order to achieve more rapid answers. Drs Moore, O'Sul-
livan and Tannock conclude that many doctors are less than
happy with clinical trials as a means of finding answers to
questions of critical importance. Their paper is of great value
and emphasises the necessity of the most careful considera-
tion of the patient's feelings and needs in developing clinical
studies. A trial which is not suitable for a doctor is most
unlikely to be appropriate for a patient.
If all patients were entered into clinical trials answers to
important therapeutic questions would quickly emerge but
Moore, O'Sullivan and Tannock demonstrate that no more
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than half the doctors treating patients with urological cancer
would be willing to enter randomised studies if themselves
suffering from the disease in question. The reason is under-
standable. To enter a trial one must accept that the concept
of random allocation has as great a chance of a successful
outcome as does that of mature clinical consideration, a
concept likely to be at odds with the clinician's instincts.
Entry to studies is much easier if both arms contain a form
of treatment with which the doctor has sympathy with some
additional therapy in one arm. Unfortunately the more inter-
esting question is sometimes whether surgery is more effective
than radiation or than chemotherapy. In this situation the
patient (and the doctor if he is also the patient) must
experience a greater sence of insecurity in accepting ran-
domisation.
In the majority of situations in urological cancer, the
overall outcome of completely different forms of therapy has
not yet been shown to be statistically different. When a new
treatment with a larger impact emerges a trial will probably
not be of great importance. In the meantime, recruitment to
clinical studies will be easier when a new form of treatment is
added to an existing regimen and in other circumstances
trials will continue to require a great deal of organisation,
energy and enthusiasm ifadequate numbers ofpatients are to
be accrued.
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